| NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial | 09/12 08:05 | globenewswire.com |
| NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/03 08:05 | globenewswire.com |
| NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report | 08/22 16:40 | globenewswire.com |
| NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer's Association International Conference | 07/30 08:05 | globenewswire.com |
| Why Is NKGen Biotech (NKGN) Stock Up 18% Today? | 07/18 11:30 | investorplace.com |
| NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference | 07/18 08:05 | globenewswire.com |
| NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors | 07/15 08:05 | globenewswire.com |
| NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 | 06/12 13:05 | globenewswire.com |
| NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 | 06/03 08:05 | globenewswire.com |
| NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 05/23 17:05 | globenewswire.com |